Featured Research

from universities, journals, and other organizations

Authors dispute 'innovation crisis' among pharmaceutical companies

Date:
August 8, 2012
Source:
University of Medicine and Dentistry of New Jersey (UMDNJ)
Summary:
Researchers dispute widely held belief that pharma companies face a "patent cliff" and argue that a "hidden business model" provides a solid cushion of steady profits from patent-protected minor variations to existing drugs.

A newly published article in the British Medical Journal disputes the widely held belief that profits at large pharmaceutical companies will plummet as the companies face a "patent cliff" when their exclusive rights expire on several blockbuster drugs. Co-authors Donald Light, PhD, of the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine, and Dr. Joel Lexchin of the University of York (Toronto) argue that a "hidden business model" provides major pharmaceutical companies with a solid cushion of steady profits from patent-protected minor variations to their existing drugs.

"Most research and development at large pharmaceutical companies is directed at developing clinically minor drugs rather than finding better drugs for unmet needs," said Light, who is also a Fellow at the Safra Center for Ethics at Harvard University. "Independent assessments indicate that 80 percent of increased costs paid by employers and insurers for pharmaceuticals is wasted on these 'new' drugs that can command higher prices under government patent protections even though they provide little or no benefit over existing medications."

The authors say claims of an "innovation crisis" in the pharmaceutical industry are a myth arising from media reports of a roughly decade-long decline in the discovery of new molecular entities (NMEs). They cite industry studies to support that conclusion. The Food and Drug Administration defines an NME as "an active ingredient that has never before been marketed in the United States in any form." According to the article by Light and Lexchin, the "crisis" simply represents a return from an unusual spike during the mid-1990s to the long term average of 15 to 25 NMEs per year.

"Companies are, of course, delighted when research breakthroughs occur, but don't depend on them," Light explained. "Instead they focus on promoting minor variations, spending 19 times as much on their marketing efforts as they do on basic research to discover new molecules."

The resultant sales of these "minor" drugs -- some of which become market blockbusters -- offset the ups and downs of drugs coming off patents, the authors note. They point to the example of Pfizer, which lost market exclusivity for Lipitor and other major sellers in 2011, but still maintained steady revenues and saw net income increase by 21 percent over the previous year.


Story Source:

The above story is based on materials provided by University of Medicine and Dentistry of New Jersey (UMDNJ). Note: Materials may be edited for content and length.


Journal Reference:

  1. D. W. Light, J. R. Lexchin. Pharmaceutical research and development: what do we get for all that money? BMJ, 2012; 345 (aug07 1): e4348 DOI: 10.1136/bmj.e4348

Cite This Page:

University of Medicine and Dentistry of New Jersey (UMDNJ). "Authors dispute 'innovation crisis' among pharmaceutical companies." ScienceDaily. ScienceDaily, 8 August 2012. <www.sciencedaily.com/releases/2012/08/120808132452.htm>.
University of Medicine and Dentistry of New Jersey (UMDNJ). (2012, August 8). Authors dispute 'innovation crisis' among pharmaceutical companies. ScienceDaily. Retrieved September 23, 2014 from www.sciencedaily.com/releases/2012/08/120808132452.htm
University of Medicine and Dentistry of New Jersey (UMDNJ). "Authors dispute 'innovation crisis' among pharmaceutical companies." ScienceDaily. www.sciencedaily.com/releases/2012/08/120808132452.htm (accessed September 23, 2014).

Share This



More Health & Medicine News

Tuesday, September 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Liberia Pleads for Help to Fight Ebola

Liberia Pleads for Help to Fight Ebola

AP (Sep. 22, 2014) Liberia's finance minister is urging the international community to quickly follow through on pledges of cash to battle Ebola. Bodies are piling up in the capital Monrovia as the nation awaits more help. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Ebola Doctor Says Border Controls Critical

Ebola Doctor Says Border Controls Critical

AP (Sep. 22, 2014) A Florida doctor who helped fight the expanding Ebola outbreak in West Africa says the disease can be stopped, but only if nations quickly step up their response and make border control a priority. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Global Ebola Aid Increasing But Critics Say It's Late

Global Ebola Aid Increasing But Critics Say It's Late

Newsy (Sep. 21, 2014) More than 100 tons of medical supplies were sent to West Africa on Saturday, but aid workers say the global response is still sluggish. Video provided by Newsy
Powered by NewsLook.com
Sierra Leone in Lockdown to Control Ebola

Sierra Leone in Lockdown to Control Ebola

AP (Sep. 21, 2014) Sierra Leone residents remained in lockdown on Saturday as part of a massive effort to confine millions of people to their homes in a bid to stem the biggest Ebola outbreak in history. (Sept. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins